+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Pediatrics Pneumococcal Therapeutics Market by Product (Drug, Vaccine), Age Group (Infants, Toddlers), Disease Type, Mode of Administration, Therapeutic Applications, End-User - Global Forecast 2025-2030- Product Image
Pediatrics Pneumococcal Therapeutics Market by Product (Drug, Vaccine), Age Group (Infants, Toddlers), Disease Type, Mode of Administration, Therapeutic Applications, End-User - Global Forecast 2025-2030- Product Image
Sale

Pediatrics Pneumococcal Therapeutics Market by Product (Drug, Vaccine), Age Group (Infants, Toddlers), Disease Type, Mode of Administration, Therapeutic Applications, End-User - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 188 Pages
  • March 2025
  • Region: Global
  • 360iResearch™
  • ID: 6055447
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Pediatrics Pneumococcal Therapeutics Market grew from USD 12.18 billion in 2024 to USD 13.15 billion in 2025. It is expected to continue growing at a CAGR of 8.14%, reaching USD 19.49 billion by 2030.

In today’s rapidly evolving healthcare landscape, pediatric pneumococcal therapeutics have emerged as a critical focus area. This executive summary provides a deep-dive into the strategic dimensions of this market, highlighting both the groundbreaking research developments and the transformative trends impacting modern therapeutic approaches. The pediatric segment, particularly vulnerable to pneumococcal infections, demands a specialized focus given the unique physiological characteristics and treatment needs of infants and toddlers. Recent scientific advances, coupled with an increased understanding of disease mechanisms and patient-specific requirements, have fostered an environment that is both innovative and adaptive.

Bringing together decades of clinical expertise, evolving regulatory frameworks, and emerging therapeutic delivery methods, this analysis underscores the imperative for dynamic and targeted interventions. The content that follows is designed to elucidate the multifaceted aspects of current treatment protocols, market segmentation, regional specificities, and the competitive landscape. It provides not only a comprehensive overview but also actionable insights for stakeholders seeking to capitalize on opportunities within this vital segment. Throughout the discussion, the narrative maintains a focus on data-driven conclusions and strategic foresight, ensuring that decision-makers and experts alike have a robust foundation on which to base their next steps.

Transformative Shifts Redefining the Therapeutic Landscape

Over the past few years, the therapeutic landscape for pediatric pneumococcal diseases has witnessed transformative shifts steered by novel research breakthroughs and emerging treatment paradigms. Advancements in drug formulations and vaccine innovations have drastically changed the way clinicians address both bacterial and viral forms of pneumonia in young patients. Traditional therapeutic regimens are being re-evaluated, with an increasing focus on precision medicine and individualized protocols that consider the unique biological makeup of infants and toddlers. This shift is further supported by technological innovations in drug delivery systems, which have enhanced the effectiveness and safety profiles of treatments.

Innovative research strategies and recalibrated clinical studies have allowed for a more granular understanding of disease progression and therapeutic outcomes. Enhanced bioavailability of both conjugate and polysaccharide vaccines has accelerated immunization programs, reducing the overall incidence of invasive and non-invasive pneumococcal diseases. Furthermore, digital health solutions and data analytics are being harnessed to optimize patient monitoring and treatment adjustments in real time. The convergence of these factors not only maximizes clinical benefits but also offers a compelling economic value proposition for healthcare providers and payers alike, ensuring that the revolution in pediatric pneumococcal care is as sustainable as it is impactful.

Key Insights Derived from Detailed Market Segmentation

A comprehensive understanding of the pediatric pneumococcal therapeutics market hinges on the nuanced segmentation that spans multiple dimensions of care and treatment options. The market is broadly segmented based on the product, which distinguishes between drugs and vaccines. Within the vaccine category, further differentiation is made between conjugate vaccines and polysaccharide vaccines, each offering unique immunogenic profiles tailored for specific patient demographics. Considering age-related factors, the pediatric market focuses on infants and toddlers, who require carefully calibrated doses and tailored therapeutic strategies.

Further insights can be drawn from an analysis based on disease type, categorizing conditions into bacterial pneumonia, mycoplasma pneumonia, and viral pneumonia; each of these infections necessitates specific clinical approaches and management patterns. The mode of administration introduces another layer of granularity, involving intramuscular, intranasal, intravenous, and oral delivery systems, and this differentiation highlights the importance of drug kinetics and patient compliance. An additional segmentation based on therapeutic applications identifies two broad categories: invasive pneumococcal diseases, which are further broken down into bacteremia and meningitis, and non-invasive pneumococcal diseases that include conditions such as otitis media and sinusitis. Finally, the market is further defined by the end-user, which systematically includes settings like clinics, homecare environments, and hospitals. This multi-dimensional segmentation framework facilitates a targeted analysis that supports effective, evidence-based decision-making in a complex therapeutic domain.

Based on Product, market is studied across Drug and Vaccine. The Vaccine is further studied across Conjugate Vaccine and Polysaccharide Vaccine.

Based on Age Group, market is studied across Infants and Toddlers.

Based on Disease Type, market is studied across Bacterial Pneumonia, Mycoplasma Pneumonia, and Viral Pneumonia.

Based on Mode of Administration, market is studied across Intramuscular, Intranasal, Intravenous, and Oral.

Based on Therapeutic Applications, market is studied across Invasive Pneumococcal Diseases and Non-Invasive Pneumococcal Diseases. The Invasive Pneumococcal Diseases is further studied across Bacteremia and Meningitis. The Non-Invasive Pneumococcal Diseases is further studied across Otitis Media and Sinusitis.

Based on End-User, market is studied across Clinics, Homecare Settings, and Hospitals.

Examination of Global Market Dynamics in Key Regions

Global market trends in pediatric pneumococcal therapeutics vary considerably across key regions. In the Americas, there is an ongoing focus on implementing aggressive immunization programs supported by robust healthcare infrastructures aimed at reducing the incidence of severe pneumococcal infections in children. In the region encompassing Europe, the Middle East, and Africa, varied healthcare challenges and economic conditions have driven a more segmented approach to therapy implementation, demanding customized protocols that address regional epidemiological trends. The integration of advanced vaccines and drugs is juxtaposed with economic strategies that ensure accessibility and sustainability, even in regions facing resource constraints.

Shifts in public policy and increasing global health initiatives are particularly evident in the Asia-Pacific region, where rapid urbanization and evolving healthcare demands propel continuous research and development. The dynamic interplay between emerging scientific discoveries and strategic health policy reforms in these regions underscores a commitment to improving pediatric health outcomes. This regional analysis not only reflects the diversity of market strategies but also serves as a critical indicator of future growth trajectories, underscoring the importance of adaptability and localized innovation in the global fight against pediatric pneumococcal diseases.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Insights on Key Industry Players and Competitive Strategies

The competitive landscape of pediatric pneumococcal therapeutics is marked by a dynamic interplay of global industry leaders who are redefining the therapeutic paradigm. Prominent companies such as AbbVie Inc., Astellas Pharma Inc., and AstraZeneca PLC have all made significant strides in developing advanced formulations and undertaking rigorous clinical trials. Aurobindo Pharma Limited, Baxter International Inc., and Bharat Biotech International Limited have also asserted their presence by focusing on innovative vaccine solutions designed for pediatric use. Industry pioneers like Biocon Limited and BioNTech SE have reconfigured development strategies with breakthrough technologies that promise improved efficacy and patient safety.

The market is further characterized by active contributions from CanSino Biologics Inc., CSL Limited, and Daiichi Sankyo Company, Limited, whose robust pipelines continue to influence market dynamics. Dr. Reddy's Laboratories Ltd. and Eli Lilly and Company have demonstrated a commitment to research excellence, while GlaxoSmithKline plc and Glenmark Pharmaceuticals enhance global access to advanced pediatric therapeutics. Other notable players including Hoffmann-La Roche AG, Johnson & Johnson, and Lupin Limited are also investing significantly in next-generation solutions. This dynamic is rounded out by contributions from Merck & Co., Inc., Moderna, Inc., and Novartis AG, along with strategic advancements from Novavax, Inc., Panacea Biotec Ltd., Pfizer Inc., Sanofi S.A., Serum Institute of India Pvt. Ltd., Sinovac Biotech Ltd., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., and Zydus Cadila. Their collective innovations and collaborative approaches continue to shape market trends and drive competitive strategies forward.

The report delves into recent significant developments in the Pediatrics Pneumococcal Therapeutics Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Astellas Pharma Inc., AstraZeneca PLC, Aurobindo Pharma Limited, Baxter International Inc., Bharat Biotech International Limited, Biocon Limited, BioNTech SE, CanSino Biologics Inc., CSL Limited, Daiichi Sankyo Company, Limited, Dr. Reddy's Laboratories Ltd., Eli Lilly and Company, GlaxoSmithKline plc, Glenmark Pharmaceuticals, Hoffmann-La Roche AG, Johnson & Johnson, Lupin Limited, Merck & Co., Inc., Moderna, Inc., Novartis AG, Novavax, Inc., Panacea Biotec Ltd., Pfizer Inc., Sanofi S.A., Serum Institute of India Pvt. Ltd., Sinovac Biotech Ltd., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., and Zydus Cadila.

Actionable Recommendations for Strategic Market Growth

To sustain growth and build competitive advantage in pediatric pneumococcal therapeutics, industry leaders must consider a strategic array of actionable recommendations. First, there is a critical need for increased investment in research and development that not only drives next-generation product innovation but also enhances the integration of digital technologies in clinical research. Organizations should prioritize collaborative initiatives that leverage cross-sector partnerships, ensuring a holistic approach to therapeutic development and improved patient outcomes.

Furthermore, companies are encouraged to adopt a multi-pronged market penetration strategy that emphasizes customized product offerings across different segments, taking into account the distinct needs of infants and toddlers as well as the multifaceted disease profiles. Strategic diversification in product offerings, whether through advanced drug formulations or tailored vaccine solutions, can unlock significant market potential. In addition, there is a distinct advantage in adopting advanced data analytics and real-world evidence methodologies to refine treatment protocols and to steer clinical decisions based on evolving market dynamics. Such data-driven insights offer actionable intelligence that can mitigate risks and maximize returns on investment. Finally, strong market positioning can be achieved by actively engaging with healthcare professionals to nurture an integrated ecosystem that supports continuous innovation and addresses unmet clinical needs.

Sustaining Innovation and Patient-Centric Growth

The pediatric pneumococcal therapeutics market is at a pivotal juncture, characterized by transformative innovations, multidimensional segmentation, and diverse regional dynamics. This executive review has underscored the critical importance of understanding the evolving landscape through granular market insights, rigorous data analysis, and an appreciation of the competitive framework. As the industry continues to pivot towards targeted therapies and precision medicine, the need for sustained innovation and strategic alignment has never been more pronounced.

The comprehensive exploration of market segmentation, regional variances, and competitive dynamics not only reinforces the growth trajectory of this domain but also illuminates the significant opportunities available for market participants. An unwavering focus on clinical excellence, coupled with agile market strategies, will be essential in addressing the specific needs of the pediatric population. As stakeholders across the healthcare spectrum align their efforts, the integration of advanced therapeutic solutions with patient-centric care emerges as a clear pathway toward improved health outcomes and lasting market success.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Growing awareness about pneumococcal diseases among parents and healthcare providers
5.1.1.2. Rising adoption of combination vaccines amplifies pediatric pneumococcal drugs
5.1.1.3. Government initiatives and policies promoting vaccination and preventative healthcare
5.1.2. Restraints
5.1.2.1. High costs associated with R&D limit the entry of new competitors
5.1.3. Opportunities
5.1.3.1. Developing age-specific formulations to better cater to different pediatric age groups
5.1.3.2. Investing in telemedicine technology to expand reach and improve patient outcomes
5.1.4. Challenges
5.1.4.1. Meeting the growing ethical concerns and transparency demands regarding drug trials in children
5.2. Market Segmentation Analysis
5.2.1. Product: Increasing adoption of conjugate vaccines due to their proven efficacy in infants
5.2.2. Therapeutic Applications: Expanding the application of pediatrics pneumococcal therapeutics in invasive pneumococcal diseases
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. Pediatrics Pneumococcal Therapeutics Market, by Product
6.1. Introduction
6.2. Drug
6.3. Vaccine
6.3.1. Conjugate Vaccine
6.3.2. Polysaccharide Vaccine
7. Pediatrics Pneumococcal Therapeutics Market, by Age Group
7.1. Introduction
7.2. Infants
7.3. Toddlers
8. Pediatrics Pneumococcal Therapeutics Market, by Disease Type
8.1. Introduction
8.2. Bacterial Pneumonia
8.3. Mycoplasma Pneumonia
8.4. Viral Pneumonia
9. Pediatrics Pneumococcal Therapeutics Market, by Mode of Administration
9.1. Introduction
9.2. Intramuscular
9.3. Intranasal
9.4. Intravenous
9.5. Oral
10. Pediatrics Pneumococcal Therapeutics Market, by Therapeutic Applications
10.1. Introduction
10.2. Invasive Pneumococcal Diseases
10.2.1. Bacteremia
10.2.2. Meningitis
10.3. Non-Invasive Pneumococcal Diseases
10.3.1. Otitis Media
10.3.2. Sinusitis
11. Pediatrics Pneumococcal Therapeutics Market, by End-User
11.1. Introduction
11.2. Clinics
11.3. Homecare Settings
11.4. Hospitals
12. Americas Pediatrics Pneumococcal Therapeutics Market
12.1. Introduction
12.2. Argentina
12.3. Brazil
12.4. Canada
12.5. Mexico
12.6. United States
13. Asia-Pacific Pediatrics Pneumococcal Therapeutics Market
13.1. Introduction
13.2. Australia
13.3. China
13.4. India
13.5. Indonesia
13.6. Japan
13.7. Malaysia
13.8. Philippines
13.9. Singapore
13.10. South Korea
13.11. Taiwan
13.12. Thailand
13.13. Vietnam
14. Europe, Middle East & Africa Pediatrics Pneumococcal Therapeutics Market
14.1. Introduction
14.2. Denmark
14.3. Egypt
14.4. Finland
14.5. France
14.6. Germany
14.7. Israel
14.8. Italy
14.9. Netherlands
14.10. Nigeria
14.11. Norway
14.12. Poland
14.13. Qatar
14.14. Russia
14.15. Saudi Arabia
14.16. South Africa
14.17. Spain
14.18. Sweden
14.19. Switzerland
14.20. Turkey
14.21. United Arab Emirates
14.22. United Kingdom
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Scenario Analysis
15.3.1. Sanofi and SK bioscience advance phase 3 PCV21 program to enhance global pediatric pneumococcal protection
15.3.2. Hong Kong Department of Health approved Pfizer's 20-valent Pneumococcal Conjugate Vaccine
15.3.3. Abbott India launched PneumoShield 14, a new pneumococcal conjugate vaccine
15.4. Strategy Analysis & Recommendation
List of Figures
FIGURE 1. PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET MULTI-CURRENCY
FIGURE 2. PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET MULTI-LANGUAGE
FIGURE 3. PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET RESEARCH PROCESS
FIGURE 4. PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, 2024 VS 2030
FIGURE 5. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 6. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY PRODUCT, 2024 VS 2030 (%)
FIGURE 9. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY PRODUCT, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2024 VS 2030 (%)
FIGURE 11. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 12. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2024 VS 2030 (%)
FIGURE 13. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 14. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 15. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 16. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2024 VS 2030 (%)
FIGURE 17. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 18. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
FIGURE 19. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 20. AMERICAS PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 21. AMERICAS PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 22. UNITED STATES PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 23. UNITED STATES PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 24. ASIA-PACIFIC PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 25. ASIA-PACIFIC PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 26. EUROPE, MIDDLE EAST & AFRICA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 27. EUROPE, MIDDLE EAST & AFRICA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 28. PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 29. PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET DYNAMICS
TABLE 7. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DRUG, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY VACCINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY CONJUGATE VACCINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY POLYSACCHARIDE VACCINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INFANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY TODDLERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY BACTERIAL PNEUMONIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MYCOPLASMA PNEUMONIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY VIRAL PNEUMONIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INTRANASAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INVASIVE PNEUMOCOCCAL DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY BACTEREMIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MENINGITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY NON-INVASIVE PNEUMOCOCCAL DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY OTITIS MEDIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY SINUSITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY NON-INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. AMERICAS PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 39. AMERICAS PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
TABLE 40. AMERICAS PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 41. AMERICAS PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 42. AMERICAS PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 43. AMERICAS PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 44. AMERICAS PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
TABLE 45. AMERICAS PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY NON-INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 48. ARGENTINA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 49. ARGENTINA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
TABLE 50. ARGENTINA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 51. ARGENTINA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 52. ARGENTINA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 53. ARGENTINA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 54. ARGENTINA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
TABLE 55. ARGENTINA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY NON-INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
TABLE 56. ARGENTINA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 57. BRAZIL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 58. BRAZIL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
TABLE 59. BRAZIL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 60. BRAZIL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 61. BRAZIL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 62. BRAZIL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 63. BRAZIL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
TABLE 64. BRAZIL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY NON-INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
TABLE 65. BRAZIL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 66. CANADA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 67. CANADA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
TABLE 68. CANADA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 69. CANADA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 70. CANADA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 71. CANADA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 72. CANADA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
TABLE 73. CANADA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY NON-INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
TABLE 74. CANADA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 75. MEXICO PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 76. MEXICO PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
TABLE 77. MEXICO PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 78. MEXICO PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 79. MEXICO PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 80. MEXICO PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 81. MEXICO PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
TABLE 82. MEXICO PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY NON-INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
TABLE 83. MEXICO PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 84. UNITED STATES PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 85. UNITED STATES PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
TABLE 86. UNITED STATES PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 87. UNITED STATES PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 88. UNITED STATES PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 89. UNITED STATES PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 90. UNITED STATES PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
TABLE 91. UNITED STATES PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY NON-INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
TABLE 92. UNITED STATES PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 93. UNITED STATES PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 94. ASIA-PACIFIC PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 95. ASIA-PACIFIC PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
TABLE 96. ASIA-PACIFIC PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 97. ASIA-PACIFIC PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 98. ASIA-PACIFIC PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 99. ASIA-PACIFIC PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 100. ASIA-PACIFIC PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
TABLE 101. ASIA-PACIFIC PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY NON-INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
TABLE 102. ASIA-PACIFIC PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 103. ASIA-PACIFIC PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 104. AUSTRALIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 105. AUSTRALIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
TABLE 106. AUSTRALIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 107. AUSTRALIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 108. AUSTRALIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 109. AUSTRALIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 110. AUSTRALIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
TABLE 111. AUSTRALIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY NON-INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
TABLE 112. AUSTRALIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 113. CHINA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 114. CHINA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
TABLE 115. CHINA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 116. CHINA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 117. CHINA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 118. CHINA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 119. CHINA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
TABLE 120. CHINA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY NON-INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
TABLE 121. CHINA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 122. INDIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 123. INDIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
TABLE 124. INDIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 125. INDIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 126. INDIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 127. INDIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 128. INDIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
TABLE 129. INDIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY NON-INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
TABLE 130. INDIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 131. INDONESIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 132. INDONESIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
TABLE 133. INDONESIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 134. INDONESIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 135. INDONESIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 136. INDONESIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 137. INDONESIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
TABLE 138. INDONESIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY NON-INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
TABLE 139. INDONESIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 140. JAPAN PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 141. JAPAN PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
TABLE 142. JAPAN PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 143. JAPAN PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 144. JAPAN PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 145. JAPAN PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 146. JAPAN PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
TABLE 147. JAPAN PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY NON-INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
TABLE 148. JAPAN PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 149. MALAYSIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 150. MALAYSIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
TABLE 151. MALAYSIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 152. MALAYSIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 153. MALAYSIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 154. MALAYSIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 155. MALAYSIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
TABLE 156. MALAYSIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY NON-INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
TABLE 157. MALAYSIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 158. PHILIPPINES PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 159. PHILIPPINES PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
TABLE 160. PHILIPPINES PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 161. PHILIPPINES PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 162. PHILIPPINES PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 163. PHILIPPINES PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 164. PHILIPPINES PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
TABLE 165. PHILIPPINES PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY NON-INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
TABLE 166. PHILIPPINES PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 167. SINGAPORE PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 168. SINGAPORE PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
TABLE 169. SINGAPORE PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 170. SINGAPORE PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 171. SINGAPORE PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 172. SINGAPORE PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 173. SINGAPORE PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
TABLE 174. SINGAPORE PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY NON-INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
TABLE 175. SINGAPORE PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 176. SOUTH KOREA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 177. SOUTH KOREA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
TABLE 178. SOUTH KOREA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 179. SOUTH KOREA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 180. SOUTH KOREA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 181. SOUTH KOREA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 182. SOUTH KOREA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
TABLE 183. SOUTH KOREA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY NON-INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
TABLE 184. SOUTH KOREA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 185. TAIWAN PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 186. TAIWAN PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
TABLE 187. TAIWAN PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 188. TAIWAN PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 189. TAIWAN PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 190. TAIWAN PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 191. TAIWAN PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
TABLE 192. TAIWAN PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY NON-INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
TABLE 193. TAIWAN PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 194. THAILAND PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 195. THAILAND PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
TABLE 196. THAILAND PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 197. THAILAND PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 198. THAILAND PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 199. THAILAND PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 200. THAILAND PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
TABLE 201. THAILAND PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY NON-INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
TABLE 202. THAILAND PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 203. VIETNAM PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 204. VIETNAM PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
TABLE 205. VIETNAM PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 206. VIETNAM PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 207. VIETNAM PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 208. VIETNAM PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 209. VIETNAM PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
TABLE 210. VIETNAM PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY NON-INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
TABLE 211. VIETNAM PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 212. EUROPE, MIDDLE EAST & AFRICA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 213. EUROPE, MIDDLE EAST & AFRICA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
TABLE 214. EUROPE, MIDDLE EAST & AFRICA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 215. EUROPE, MIDDLE EAST & AFRICA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 216. EUROPE, MIDDLE EAST & AFRICA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 217. EUROPE, MIDDLE EAST & AFRICA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 218. EUROPE, MIDDLE EAST & AFRICA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
TABLE 219. EUROPE, MIDDLE EAST & AFRICA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY NON-INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
TABLE 220. EUROPE, MIDDLE EAST & AFRICA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 221. EUROPE, MIDDLE EAST & AFRICA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 222. DENMARK PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 223. DENMARK PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
TABLE 224. DENMARK PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 225. DENMARK PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 226. DENMARK PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 227. DENMARK PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 228. DENMARK PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
TABLE 229. DENMARK PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY NON-INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
TABLE 230. DENMARK PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 231. EGYPT PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 232. EGYPT PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
TABLE 233. EGYPT PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 234. EGYPT PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 235. EGYPT PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 236. EGYPT PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 237. EGYPT PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
TABLE 238. EGYPT PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY NON-INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
TABLE 239. EGYPT PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 240. FINLAND PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 241. FINLAND PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
TABLE 242. FINLAND PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 243. FINLAND PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 244. FINLAND PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 245. FINLAND PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 246. FINLAND PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
TABLE 247. FINLAND PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY NON-INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
TABLE 248. FINLAND PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 249. FRANCE PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 250. FRANCE PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
TABLE 251. FRANCE PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 252. FRANCE PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 253. FRANCE PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 254. FRANCE PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 255. FRANCE PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
TABLE 256. FRANCE PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY NON-INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
TABLE 257. FRANCE PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 258. GERMANY PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 259. GERMANY PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
TABLE 260. GERMANY PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 261. GERMANY PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 262. GERMANY PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 263. GERMANY PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 264. GERMANY PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
TABLE 265. GERMANY PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY NON-INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
TABLE 266. GERMANY PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 267. ISRAEL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 268. ISRAEL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
TABLE 269. ISRAEL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 270. ISRAEL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 271. ISRAEL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 272. ISRAEL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 273. ISRAEL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
TABLE 274. ISRAEL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY NON-INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
TABLE 275. ISRAEL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 276. ITALY PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 277. ITALY PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
TABLE 278. ITALY PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 279. ITALY PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 280. ITALY PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 281. ITALY PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 282. ITALY PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
TABLE 283. ITALY PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY NON-INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
TABLE 284. ITALY PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY

Companies Mentioned

  • AbbVie Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Aurobindo Pharma Limited
  • Baxter International Inc.
  • Bharat Biotech International Limited
  • Biocon Limited
  • BioNTech SE
  • CanSino Biologics Inc.
  • CSL Limited
  • Daiichi Sankyo Company, Limited
  • Dr. Reddy's Laboratories Ltd.
  • Eli Lilly and Company
  • GlaxoSmithKline plc
  • Glenmark Pharmaceuticals
  • Hoffmann-La Roche AG
  • Johnson & Johnson
  • Lupin Limited
  • Merck & Co., Inc.
  • Moderna, Inc.
  • Novartis AG
  • Novavax, Inc.
  • Panacea Biotec Ltd.
  • Pfizer Inc.
  • Sanofi S.A.
  • Serum Institute of India Pvt. Ltd.
  • Sinovac Biotech Ltd.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • Zydus Cadila

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages188
PublishedMarch 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 13.15 Billion
Forecasted Market Value ( USD ) by 2030 $ 19.49 Billion
Compound Annual Growth Rate8.1%
Regions CoveredGlobal
No. of Companies Mentioned30

Related Topics

Related Reports

Pediatric Vaccines Market by Vaccine Type, by Technology, by Indication, by Distribution Channel, and by Region - Product Image

Pediatric Vaccines Market by Vaccine Type, by Technology, by Indication, by Distribution Channel, and by Region

  • Report
  • 200 Pages
  • Global
From
Pediatric Vaccines Market Size, Share & Trends Analysis Report By Type (Monovalent, Multivalent), By Technology (Live Attenuated Vaccines), By Application (Cancer), By Region, And Segment Forecasts, 2024 - 2030 - Product Image

Pediatric Vaccines Market Size, Share & Trends Analysis Report By Type (Monovalent, Multivalent), By Technology (Live Attenuated Vaccines), By Application (Cancer), By Region, And Segment Forecasts, 2024 - 2030

  • Report
  • 100 Pages
  • Global
From
Pediatric Vaccines Market by Technology, Vaccine, Indication, End User - Global Forecast 2025-2030 - Product Image

Pediatric Vaccines Market by Technology, Vaccine, Indication, End User - Global Forecast 2025-2030

  • Report
  • 195 Pages
  • Global
From
Pediatric Vaccine Market - Forecasts from 2024 to 2029 - Product Image

Pediatric Vaccine Market - Forecasts from 2024 to 2029

  • Report
  • 130 Pages
  • Global
From
Pediatric Vaccine Market Opportunities and Strategies to 2033 - Product Image

Pediatric Vaccine Market Opportunities and Strategies to 2033

  • Report
  • 286 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.